Abstract
To investigate the SDHAF2 gene and its effect on primary hyperparathyroidism. Parathyroid tumors causing primary hyperparathyroidism (pHPT) are one of the more common endocrine neoplasias. Loss of heterozygosity at chromosome 11q13 is the most common chromosomal aberration in parathyroid tumors occurring in about 40% of sporadic tumors. Only 15–19% display somatic mutations in the MEN1 gene, which suggest that this chromosomal region may harbor additional genes of importance in parathyroid tumor development. The SDHAF2 (formerly SDH5) gene is a recently identified neuroendocrine tumor suppressor gene at this locus, and inherited mutations of the SDHAF2 gene has been linked to familial paraganglioma. We demonstrate that the SDHAF2 gene is expressed in parathyroid tissue using RT-PCR. Because detection of inactivating mutations is the major criterion for validating a candidate tumor suppressor, we used automated sequencing of the coding region and intron/exon boundaries in 80 sporadic parathyroid adenomas from patients with pHPT. A known polymorphisms (A to G substitution; rs879647) was identified in 9/80 parathyroid tumors but no tumor-specific somatic mutational aberrations, such as nonsense, frameshift, or other inactivating mutations were identified. The SDHAF2 gene is expressed in parathyroid tissue. However, somatic mutations of the SDHAF2 tumor suppressor gene are unlikely to frequently contribute to parathyroid tumor development in sporadic pHPT.
Similar content being viewed by others
References
T. Carling, Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr. Opin. Oncol. 17, 7–12 (2005)
E. Lundgren, J. Rastad et al., Population-based health screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 121, 287–294 (1997)
S.C. Chandrasekharappa, S.C. Guru et al., Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276, 404–407 (1997)
J.D.R.C. Carpten, A. Villablanca et al., HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat. Genet. 32, 676–680 (2002)
A. Arnold, H.G. Kim, Clonal loss of one chromosome 11 in a parathyroid adenoma. J. Clin. Endocrinol. Metab. 69, 496–499 (1989)
A. Arnold, H.G. Kim et al., Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in parathyroid adenoma. J. Clin. Invest. 83, 2034–2040 (1989)
C. Heppner, M.B. Kester et al., Somatic mutations of the MEN1 gene in parathyroid tumours. Nat. Genet. 16, 375–378 (1997)
T. Carling, P. Correa et al., Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 83, 2960–2963 (1998)
F. Farnebo, B.-T. Teh, S. Kytölä et al., Alterations of the MEN1 gene in sporadic parathyroid tumors. J. Clin. Endocrinol. Metab. 83, 2627–2630 (1998)
T. Carling, Molecular pathology of parathyroid tumors. Trends Endocrinol. Metab. 12, 53–58 (2001)
H.X. Hao, O. Khalimonchuk et al., SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325, 1139–1142 (2009)
H.P. Neumann, B. Bausch et al., Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346, 1459–1466 (2002)
B.E. Baysal, Clinical and molecular progress in hereditary paraganglioma. J. Med. Genet. 45, 689–694 (2008)
B.E. Baysal, R.E. Ferrell et al., Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287, 848–851 (2000)
J.P. Bayley, H.P. Kunst et al., SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 11, 366–372 (2010)
I.P. Tomlinson, N.A. Alam et al., Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30, 406–410 (2002)
H. Yan, D.W. Parsons et al., IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009)
J. Costa-Guda, T. Tokura, S.I. Roth et al., Mitochondrial DNA mutations in oxyphilic and chief cell parathyroid adenomas. BMC Endocr. Disord. 7, 8 (2007)
J.J. Yeh, K.L. Lunetta et al., Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene 19(16), 2060–2066 (2000)
T. Carling, A. Kindmark et al., Vitamin D receptor genotypes in primary hyperparathyroidism. Nat. Med. 1, 1309–1311 (1995)
T. Carling, J. Rastad et al., Reduced vitamin D receptor mRNA levels in parathyroid glands of primary and secondary hyperparathyroidism. J. Clin. Endocrinol. 85, 2000–2003 (2000)
E.R. Fearon, C.V. Dang, Cancer genetics: tumor suppressor meets oncogene. Curr. Biol. 9, R62–R65 (1999)
Acknowledgments
This study was in part supported by the Ohse Research Award (to T.C.).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Starker, L.F., Delgado-Verdugo, A., Udelsman, R. et al. Expression and somatic mutations of SDHAF2 (SDH5), a novel endocrine tumor suppressor gene in parathyroid tumors of primary hyperparathyroidism. Endocr 38, 397–401 (2010). https://doi.org/10.1007/s12020-010-9399-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-010-9399-0